ESC2025 Premium Access

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial

Congress Presentation

About the speaker

Doctor Xueyi Wu

Fuwai Hospital, CAMS and PUMC, Beijing (China)
1 follower

5 more presentations in this session

The importance of coronary flow velocity reserve in predicting cardiac mortality and heart failure in hypertrophic cardiomyopathy

Speaker: Associate Professor M. Tesic (Belgrade, RS)

Thumbnail

Real-world outcomes of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy: global evidence from COLLIGO-HCM

Speaker: Doctor A. Adler (Toronto, CA)

Thumbnail

The icelandic hypertrophic cardiomyopathy project: a recall-by-genotype study on MYBPC3 founder mutation carriers. echocardiographic data and b-type natriuretic peptide measurement.

Speaker: Doctor O. Gunnarsdottir (Reykjavik, IS)

Thumbnail

Multiparametric CMR detects a higher burden of microstructural and metabolic abnormalities in sarcomeric HCM compared to non-sarcomeric HCM

Speaker: Doctor Z. Ashkir (Oxford, GB)

Thumbnail

Extended holter monitoring in hypertrophic cardiomyopathy: the predictive value of early versus late nonsustained ventricular tachycardia detection

Speaker: Doctor C. Chaumont (Rouen, FR)

Thumbnail

Access the full session

Advancing care in hypertrophic cardiomyopathy

Speakers: Doctor X. Wu, Associate Professor M. Tesic, Doctor A. Adler, Doctor O. Gunnarsdottir, Doctor Z. Ashkir...
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations